27MO BDTX-1535, a CNS penetrant, irreversible inhibitor of intrinsic and acquired resistance EGFR mutations, demonstrates preclinical efficacy in NSCLC and GBM PDX models
Titel:
27MO BDTX-1535, a CNS penetrant, irreversible inhibitor of intrinsic and acquired resistance EGFR mutations, demonstrates preclinical efficacy in NSCLC and GBM PDX models
Auteur:
Lucas, M.C. Merchant, M. O'Connor, M. Smith, S. Trombino, A. Zhang, W-Y. Simon, J. Eathiraj, S. Waters, N. Buck, E.